StreetInsider.com News Articles

Rockwell Medical Technologies (RMTI) PT Lowered to $20 at Maxim Group

Tue, 18 Aug 2026 13:59:05 -0400

Maxim Group analyst Anthony Vendetti lowered the price target on Rockwell Medical Technologies (NASDAQ: RMTI) to $20.00 while maintaining a Buy rating.

Form 8-K ROCKWELL MEDICAL, INC. For: Aug 13

Thu, 13 Aug 2026 07:27:00 -0400

si-local-file:///var/storage/secattach/20260813/26916438.html

Form 8-K ROCKWELL MEDICAL, INC. For: Aug 13

Thu, 13 Aug 2026 07:27:00 -0400

si-local-file:///var/storage/secattach/20260813/26916438.html

Form 10-Q ROCKWELL MEDICAL, INC. For: Jun 30

Thu, 13 Aug 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26916180.html

Form 10-Q ROCKWELL MEDICAL, INC. For: Jun 30

Thu, 13 Aug 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26916180.html

Rockwell Medical (RMTI) Misses Q2 EPS by 1c

Thu, 13 Aug 2026 06:14:29 -0400

Rockwell Medical (NASDAQ: RMTI) reported Q2 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $17.78 million versus the consensus estimate of $17.84 million.

For earnings history and earnings-related data on Rockwell Medical (RMTI) click here.

Form 8-K ROCKWELL MEDICAL, INC. For: Aug 13

Thu, 13 Aug 2026 06:14:00 -0400

si-local-file:///var/storage/secattach/20260813/26915852.html

Form 8-K ROCKWELL MEDICAL, INC. For: Aug 13

Thu, 13 Aug 2026 06:14:00 -0400

si-local-file:///var/storage/secattach/20260813/26915852.html

Rockwell Medical Announces Second Quarter 2026 Results

Thu, 13 Aug 2026 06:00:00 -0400

Net Sales for the second quarter 2026 were $17.8 million, an increase over net sales for the first quarter 2026 and an 11% increase over the same period in 2025
Gross Profit for the second quarter 2026 increased 30% over the same period in 2025 and Gross Margin expanded to 18% primarily driven by lower manufacturing costs and higher volume
Generated $2.1 million of Cash Flow from Operations in the second quarter 2026, increasing cash position at June 30, 2026 to $24.8 million
On track to achieve full-year guidance with emphasis on top line growth, improving gross margins and positive cash flow

Rockwell Medical Announces Second Quarter 2026 Results

Thu, 13 Aug 2026 06:00:00 -0400

Net Sales for the second quarter 2026 were $17.8 million, an increase over net sales for the first quarter 2026 and an 11% increase over the same period in 2025
Gross Profit for the second quarter 2026 increased 30% over the same period in 2025 and Gross Margin expanded to 18% primarily driven by lower manufacturing costs and higher volume
Generated $2.1 million of Cash Flow from Operations in the second quarter 2026, increasing cash position at June 30, 2026 to $24.8 million
On track to achieve full-year guidance with emphasis on top line growth, improving gross margins and positive cash flow

Rockwell Medical Announces Second Quarter 2026 Results

Thu, 13 Aug 2026 06:00:00 -0400

Net Sales for the second quarter 2026 were $17.8 million, an increase over net sales for the first quarter 2026 and an 11% increase over the same period in 2025
Gross Profit for the second quarter 2026 increased 30% over the same period in 2025 and Gross Margin expanded to 18% primarily driven by lower manufacturing costs and higher volume
Generated $2.1 million of Cash Flow from Operations in the second quarter 2026, increasing cash position at June 30, 2026 to $24.8 million
On track to achieve full-year guidance with emphasis on top line growth, improving gross margins and positive cash flow

Rockwell Medical Announces Second Quarter 2026 Results

Thu, 13 Aug 2026 06:00:00 -0400

Net Sales for the second quarter 2026 were $17.8 million, an increase over net sales for the first quarter 2026 and an 11% increase over the same period in 2025
Gross Profit for the second quarter 2026 increased 30% over the same period in 2025 and Gross Margin expanded to 18% primarily driven by lower manufacturing costs and higher volume
Generated $2.1 million of Cash Flow from Operations in the second quarter 2026, increasing cash position at June 30, 2026 to $24.8 million
On track to achieve full-year guidance with emphasis on top line growth, improving gross margins and positive cash flow

Rockwell Medical names Brian Cox VP of quality and regulatory compliance

Wed, 22 Jul 2026 06:01:58 -0400

Rockwell Medical, Inc. (Nasdaq: RMTI) has appointed Brian Cox as Vice President, Quality and Regulatory Compliance, according to a company statement.

Cox brings more than 20 years of healthcare experience in medical device development and manufacturing, quality, regulatory compliance, operations, and program management. He has held senior roles at Abbott and Johnson & Johnson, as well as smaller medical device manufacturers.

His background includes quality systems, regulatory readiness, audit oversight, product development, program management, and design controls, along with expertise in Class I, II, and III medical devices.

"As we advance these priorities, it is critical that we continue to invest in compliance,

Rockwell Medical names Brian Cox VP of quality and regulatory compliance

Wed, 22 Jul 2026 06:01:58 -0400

Rockwell Medical, Inc. (Nasdaq: RMTI) has appointed Brian Cox as Vice President, Quality and Regulatory Compliance, according to a company statement.

"As we advance these priorities, it is critical that we continue to invest in compliance,

Rockwell Medical Advances Quality and Regulatory Leadership

Wed, 22 Jul 2026 06:00:00 -0400

Names Brian Cox Vice President, Quality and Regulatory Compliance

WIXOM, Mich.--(BUSINESS WIRE)-- Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Brian Cox has joined the Company as Vice President, Quality and Regulatory Compliance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722472051/en/